Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00126997
Status:
COMPLETED
Last Update Posted:
2016-09-21
First Post:
2005-08-04
Brief Title:
Immunogenicity and Safety of Combined Vaccine to Prevent Measles Mumps Rubella and Chickenpox Diseases
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Blinded Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline GSK Biologicals Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to assess the immunogenicity and safety of GlaxoSmithKline GSK Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None